With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Brush up on your midgut anatomy because the quality of life data from the 2017 NETTER-1 trial shows Lu-177 Dotatate, as compared to octreotide, enables patients with GI neuroendocrine tumors not only to live (much!) longer without disease but also to live better. | Strosberg, J Clin Oncol 2018